FATE - Fate Therapeutics Inc. (FATE) Q1 2024 Earnings Call Transcript
2024-05-11 18:12:07 ET
Fate Therapeutics, Inc. (FATE)
Q1 2024 Results Conference Call
May 09, 2024 05:00 PM ET
Company Participants
Scott Wolchko - President and CEO
Ed Dulac - CFO
Bob Valamehr - Chief Research and Development Officer
Conference Call Participants
Michael Yee - Jefferies
Ashiq Mubarack - Citi
Jeff LaRosa - Leerink Partners
Rohit Bhasin - Morgan Stanley
Li Watsek - Cantor Fitzgerald
Greg Williams - TD Cowen
Carolina Ibanez-Ventoso - Stifel
Alex Bouilloux - Barclays
Yanan Zhu - Wells Fargo Securities
Bill Maughan - Canaccord Genuity
Ethan Markowski - Needham & Company
Presentation
Operator
Welcome to the Fate Therapeutics First Quarter 2024 Financial Results Conference Call [Operator Instructions]. This call is being webcast live on the Investors section of Fate's Web site at fatetherapeutics.com. As a reminder, today's call is also being recorded.
I would now like to turn -- I would now like to introduce Scott Wolchko, President and CEO of Fate Therapeutics. Please go ahead.
Scott Wolchko
Thank you. Good afternoon, and thanks, everyone, for joining us for the Fate Therapeutics First Quarter 2024 Financial Results Call. Shortly after 4:00 p.m. Eastern Time today, we issued a press release with these results, which can be found on the Investors section of our website under Press Releases. In addition, our Form 10-Q for the quarter ended March 31, 2024, was filed shortly thereafter and can be found on the Investors section of our website under Financial Information. Before we begin, I would like to remind everyone that except for statements of historical facts, the statements made by management and responses to questions on this conference call are forward-looking statements under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements involve risks and uncertainties that can cause actual results to differ materially from those in such forward-looking statements. Please see the forward-looking statement disclaimer on the company's earnings press release issued after the close of market today as well as the risk factors included in our Form 10-Q for the quarter ended March 31, 2024, that was filed with the SEC today. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made, as facts and circumstances underlying these forward-looking statements may change. Except as required by law, Fate Therapeutics disclaims any obligation to update these forward-looking statements to reflect future information, events or circumstances. Joining me on today's call are Ed Dulac, our Chief Financial Officer; and Dr. Bob Valamehr, our Chief Research and Development Officer....
Fate Therapeutics, Inc. (FATE) Q1 2024 Earnings Call Transcript